Health New England says it achieved 93% utilization by requiring prior authorization.
A nonprofit health plan in Massachusetts recently said it has saved $1.7 million over the past year since emphasizing use of biosimilar infliximab, reaching 93% utilization in collaboration with Magellan Rx Management.
Health New England said its medical pharmacy program began the initiative on January 1, 2019.
“We were looking for ways to drive cost savings in this class without compromising patient care,” said Andrew J. Colby, RPh, MBA, Health New England's pharmacy director, in a recent statement. “Biosimilars offer an important opportunity to reduce costs for both payers and patients, while ensuring patients can continue treatment with a product that provides the same levels of clinical efficacy and safety they have experienced while taking the innovator drug.”
The reference product, Remicade, remains the highest-spend drug on the medical benefit, the company said. Biosimilars can cost as much as 35% less than originator products, the company noted.
Payers spend approximately $43,000 per patient annually on this product, and expenditures have continued to grow, including a 14% increase in Remicade per-member-per-month (PMPM) spend for commercial health plans from 2016 to 2017, according to Magellan.
Autoimmune PMPM drug costs are expected to increase 90%, from $1.40 to $2.66, by 2022 Magellan noted in last year’s Medical Pharmacy Trends report.
Working with Magellan, Health New England said it turned to a prior authorization program to drive utilization to biosimilar infliximab, with pharmacists using “the most updated peer-reviewed literature to develop a robust clinical policy.”
“We were able to collaborate with our provider network to ensure a smooth transition to the biosimilar product while providing patients with the same quality of care,” said Colby. “Our positive experience with this effort further supports similar initiatives for other therapeutic categories, such as oncology, in mitigating rising medical benefit trend and spend.”
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.